Brenda Motheral, RPh, MBA, PhD, and John Neal, MBA
Recently published data from a survey of commercial health plans reveal the latest trends and emerging strategies in oncology management.
Aimee Tharaldson, PharmD
Anticipated near-term specialty drug approvals include new therapies for cancer, orphan conditions, high cholesterol, and asthma.
Kelly Mathews, PharmD
Mobile adherence apps are a great boon to patients who face the responsibility of taking oral chemotherapy drugs as directed without in-person supervision by clinicians.
Gerd Binnig, PhD
Pharmaceutical companies and clinical oncology teams are collaborating to harness large sets of patient data, paving the way for more informed and individualized decision-making about treatments.
Dan Steiber, RPh, Specialty Pharmacy Times Editor-in-Chief
As oncology spending rises, insurers and manufacturers are looking to specialty pharmacy programs to maximize the effectiveness of cancer therapies.
Michael R. Hess and Shannon L. Wiley
There are several key factors a specialty pharmacy must consider when deciding whether to participate in a limited distribution network.